

SECTOR FOCUS: SENIOR CARE / LONG-TERM CARE

WWW.MERCERCAPITAL.COM

Introduction

Senior care is a large and growing industry in the United States. Growth is primarily predicated on demographic shifts, with an aging population likely to need both general and specialized living assistance. The industry includes a wide range of services, from independent living and assisted living to skilled nursing and hospice care. Most long-term care offerings of various stripes are also generally understood to be part of the senior care industry.

Demographic Trends and Demand Drivers

The aging population in the U.S. is the primary driver of growth in the senior care industry. The elderly population (persons aged 65 and above) in the U.S. totaled 60 million in 2023 (18% of the population). The U.S. Census Bureau **estimates** that the number of elderly individuals will reach approximately 93 million by 2065, representing more than 25% of the total population. This demographic shift will lead to a corresponding increase in the demand for various types of senior care services.

Long-term gains in life expectancy and advancements in healthcare have resulted in more individuals surviving until advanced age (even within the elderly group). Many of these individuals will experience chronic conditions, mobility issues, cognitive decline, or other medical needs that require assistance. As a result, significant growth is expected in the demand for care services ranging from in-home assistance to institutional care in nursing homes or memory care facilities.

In This Issue

| SECTOR FOCUS Senior Care / Long-Term Care | |
|---|----|
| Introduction | 1 |
| Demographic Trends and Demand Drivers | 1 |
| Revenue Size and Payers | 2 |
| Continuum of Care | 2 |
| Private Equity Involvement | 3 |
| Challenges and Opportunities | 3 |
| HEALTHCARE SNAPSHOT | |
| Stocks | 4 |
| IPOs | 11 |
| Private Equity M&A | 12 |
| Healthcare Facilities M&A | 13 |
| About Mercer Capital | 14 |

Learn More about Mercer Capital & our Healthcare Facilities Services at www.mercercapital.com



Revenue Size and Payers

By one **estimate**, the U.S. senior care industry (broadly defined as long-term services and supports) accounted for \$415 billion in spending in 2022. Home and community-based services represented the majority (\$284 billion), with spending at institutional settings making up the balance of the total. Medicaid paid for the largest share of the spending (61%), followed by out-of-pocket (17%), and other public and private payers. Spending is projected to grow steadily in response to the increasing elderly population and demand for both skilled and non-skilled care services.

The revenue generated by the senior care industry is distributed across various sub-sectors, including home healthcare, nursing homes, assisted living, and hospice care. Each of these areas has experienced distinct growth patterns and presents unique opportunities and challenges.

Continuum of Care

The continuum of care in the senior care industry refers to the range of services available to older adults, from independent living to intensive medical care.

- 1. Home Health Care: Home healthcare provides medical and non-medical services to seniors in their homes. This is the fastest-growing sector of the senior care industry, with revenues estimated at \$103 billion in 2020 and projected to be \$173 billion by 2026. Technological advancements in telehealth, patient preference for aging in place, and cost savings are fueling growth in this area.
- 2.Independent Living: Independent living communities cater to older adults who are generally healthy and do not need medical assistance but prefer to live in a community with services such as meals, social activities, and

housekeeping. By one **estimate**, there are more than 750,000 independent living housing units in the U.S. Occupancy of the units is **estimated** to approach 90%. Projected growth in independent living is tied closely to increasing demand for retirement communities.

- 3. Assisted Living: Assisted living facilities provide support with activities of daily living such as bathing, dressing, and medication management. The U.S. had more than 1 million residents in assisted living communities in 2020, supported by about 1.2 million licensed beds across more than 32,000 facilities. More than half of these residents are 85 or older and two-thirds are female. The national median cost for assisted living services is approximately \$64,000 annually. The growth of assisted living is projected to be in line with the aging population, increasing by approximately 4–6% annually.
- 4. Skilled Nursing Facilities (SNF): Skilled nursing facilities offer more intensive medical care for seniors who have serious health conditions, require rehabilitation, or need assistance with a broad range of medical needs. In 2020, there were approximately 1.3 million nursing home residents in the U.S., with 1.6 million licensed beds. Revenues totaled \$130.1 billion that year. Growth in this sector is understood to be relatively slower due to rising preference for home care and staffing challenges.
- 5. Memory Care: This sub-sector includes care for seniors with Alzheimer's disease, dementia, and other forms of cognitive impairment. Memory care facilities are often separate from assisted living, providing specialized care. The number of memory care beds in the U.S. was estimated to be around 255,000 in 2020. According to an estimate, total revenue for the sector was \$5.8 billion in 2022, and is projected to grow approximately 5% annually over the medium term.



6. Hospice Care: Hospice care is provided for seniors with a terminal illness, focusing on comfort rather than curative treatment. The hospice market serves **approximately** 1.5 million patients annually. Revenue for the U.S. hospice market is **estimated** at approximately \$30 billion for 2024, with steady growth projected at 4–6% annually through 2030.

Private Equity Involvement

In 2024, **around 25%** of hospices were owned by private equity and another 40% were operated by other for-profit entities. Between 2011 and 2019, there were more than 400 private equity **transactions** involving hospices, and the majority involved purchase of previously nonprofit agencies.

By one **estimate**, PE investments represent approximately 5% of all nursing home (SNF) facilities. Real estate investment trusts (REITs) are estimated to own 9% of nursing home facilities in the U.S.

Challenges and Opportunities

While the senior care industry faces a variety of challenges, including staffing shortages, regulatory pressures, and rising costs, there are also numerous opportunities for growth. Advances in technology, such as telemedicine, artificial intelligence, and remote patient monitoring, offer new ways to provide care and improve efficiency. Additionally, the demand for non-medical services, such as home modifications and social engagement programs, presents growth avenues.

| Healthcare Chain | PE Backer | Number of Centers | Specialty | Acquisition Price |
|--|-------------------------------------|-------------------|------------------|-------------------|
| Genesis HealthCare | Pinta Capital Partners | 220 | Skilled Nursing | Undisclosed |
| Accordius, Pelican HC, and Orchid Cove | Portopiccolo Group | 136 | Skilled Nursing | Undisclosed |
| LaVie Care Centers | Formation Capital | 43 | Skilled Nursing | Undisclosed |
| Discovery Senior Living | Lee Equity Partners | 350 | Skilled/Assisted | Undisclosed |
| Life Care Services | Redwood Capital & McCarthy Capital | 140 | CCRC/Assisted | Undisclosed |
| Marquis Health Services | Tryko Partners | 68 | Skilled Nursing | Undisclosed |
| Brickyard Healthcare | Filmore Capital | 23 | Skilled Nursing | Undisclosed |
| Plum Healthcare | GI Partners | 50 | Skilled Nursing | \$150M |
| Legacy Healthcare | Cascade Capital Partners | 60 | Skilled Nursing | Undisclosed |
| Covenant Care | Centre Partners & Stockwell Capital | 25 | Skilled Nursing | Undisclosed |
| Atria Senior Living | Fremont Group | 274 | Assisted Living | \$365M |
| Erickson Senior Living | Redwood Capital | 24 | Assisted Living | Undisclosed |
| CFP Living | Chicago Pacific Founders | 65 | Assisted Living | Undisclosed |
| Benchmark Senior Living | KKR Real Estate Partners | 61 | Assisted Living | \$1.9B |
| Spectrum Retirement Communities | Fisher Capital Partners | 38 | Assisted Living | Undisclosed |
| The Arbor Company | Arcapita Group | 49 | Assisted Living | Undisclosed |
| Gentiva | Clayton, Dubilier, and Rice | 590 | Hospice | \$2.8B |
| Compassus | TowerBrook Capital Partners | 270 | Hospice | \$1B |
| AccentCare | Advent International | 250 | Hospice | Undisclosed |
| Agape Care Group | Ridgemont Equity Partners | 14 | Hospice | Undisclosed |
| Traditions Health | Dorilton Capital | 117 | Hospice | Undisclosed |
| St. Croix Hospice | H.I.G. Capital | 83 | Hospice | \$580M |



Healthcare Equipment & Supplies

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Rev | /enue | EV/EB | ITDA | Price | EPS | Gross | EBITDA | ROE |
|--------|-------------------------------|-------------|----------|----------|----------|---------|------------|---------|--------|--------|-------|-------|-------|-------|-------|--------|---------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| BAX | Baxter International Inc. | 30.28 | \$15,533 | \$23,521 | \$10,636 | \$1,885 | -11.0% | -8.4% | 2.21x | 2.02x | 12.5x | 9.8x | NM | 11.8x | 39.6% | 17.7% | -4.2% |
| BDX | Becton, Dickinson and Company | 172.25 | 49,368 | 67,955 | 20,178 | 5,164 | -23.8% | -24.9% | 3.37x | 3.05x | 13.2x | 10.6x | 33.4x | 12.2x | 45.4% | 25.6% | 6.6% |
| CAH | Cardinal Health, Inc. | 168.00 | 40,098 | 45,501 | 226,827 | 2,856 | 22.5% | 71.8% | 0.20x | 0.19x | 15.9x | 12.7x | 26.3x | 18.6x | 3.3% | 1.3% | -27.7% |
| COR | Cencora, Inc. | 299.85 | 58,118 | 66,072 | 293,959 | 4,152 | 8.1% | 34.1% | 0.22x | 0.19x | 15.9x | 13.0x | 34.9x | 18.1x | 3.3% | 1.4% | 209.1% |
| HOLX | Hologic, Inc. | 65.16 | 14,521 | 15,426 | 4,030 | 1,272 | 6.2% | -12.1% | 3.83x | 3.71x | 12.1x | 11.4x | 27.3x | 15.2x | 60.7% | 31.6% | 15.6% |
| ISRG | Intuitive Surgical, Inc. | 543.41 | 194,768 | 190,358 | 8,352 | 2,826 | 9.5% | 24.6% | 22.79x | 19.08x | 67.4x | 46.7x | 79.6x | 67.4x | 67.5% | 33.8% | 15.6% |
| MCK | McKesson Corporation | 732.78 | 91,674 | 93,777 | 359,051 | 5,416 | 8.8% | 25.0% | 0.26x | 0.23x | 17.3x | 13.9x | 28.5x | 19.6x | 3.6% | 1.5% | -211.4% |
| RMD | ResMed Inc. | 258.00 | 37,762 | 37,657 | 4,685 | 1,534 | 16.1% | 38.0% | 8.04x | 6.90x | 24.6x | 18.5x | 29.0x | 25.3x | 57.4% | 32.7% | 22.7% |
| TMO | Thermo Fisher Scientific Inc. | 405.46 | 153,059 | 181,466 | 42,879 | 10,842 | -16.0% | -25.2% | 4.23x | 4.10x | 16.7x | 16.5x | 23.8x | 17.8x | 41.4% | 25.3% | 13.1% |
| WST | West Pharmaceutical Services, | 218.80 | 15,720 | 15,623 | 2,893 | 749 | -0.6% | -32.6% | 5.40x | 5.16x | 20.9x | 21.1x | 34.3x | 34.4x | 34.5% | 25.9% | 17.7% |
| Median | | | \$44,733 | \$55,787 | \$15,407 | \$2,841 | 7.1% | 8.1% | 3.60x | 3.38x | 16.3x | 13.4x | 29.0x | 18.4x | 40.5% | 25.4% | 14.3% |

Source: CapIQ with Mercer Analysis

Pharmaceuticals

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Rev | /enue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|------------------------------|-------------|-----------|-----------|----------|----------|------------|---------|--------|--------|-------|-------|--------|-------|-------|--------|--------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| ABT | Abbott Laboratories | \$136.01 | \$236,635 | \$243,334 | \$41,950 | \$10,714 | 3.3% | 31.8% | 5.80x | 5.35x | 22.7x | 20.2x | 17.7x | 25.8x | 55.6% | 25.5% | 30.9% |
| ABBV | AbbVie Inc. | 185.62 | 327,880 | 392,770 | 56,334 | 26,718 | -10.0% | 9.0% | 6.97x | 6.46x | 14.7x | 13.2x | 79.3x | 16.5x | 70.4% | 47.4% | 62.3% |
| AMGN | Amgen Inc. | 279.21 | 150,133 | 198,704 | 33,424 | 15,157 | -9.0% | -10.2% | 5.94x | 5.62x | 13.1x | 11.0x | 25.5x | 13.4x | 68.7% | 45.3% | 67.6% |
| AZN | AstraZeneca PLC | 138.65 | 214,997 | 243,007 | 54,073 | 17,567 | -5.6% | -10.8% | 4.49x | 4.11x | 13.8x | 11.8x | 26.3x | 14.9x | 82.2% | 32.5% | 17.6% |
| BMY | Bristol-Myers Squibb Company | 46.29 | 94,204 | 133,408 | 48,300 | 19,407 | -22.3% | 12.1% | 2.76x | 2.92x | 6.9x | 7.6x | 17.3x | 7.1x | 75.3% | 40.2% | -39.0% |
| LLY | Eli Lilly and Company | 779.53 | 699,812 | 734,815 | 45,043 | 19,268 | -3.2% | -14.7% | 16.31x | 11.72x | 38.1x | 23.6x | 63.4x | 31.2x | 81.3% | 42.8% | 84.3% |
| GILD | Gilead Sciences, Inc. | 110.87 | 137,914 | 154,071 | 28,754 | 13,454 | -0.4% | 61.5% | 5.36x | 5.33x | 11.5x | 9.5x | 23.4x | 13.6x | 78.3% | 46.8% | 2.3% |
| JNJ | Johnson & Johnson | 152.75 | 367,528 | 380,999 | 88,821 | 29,940 | -0.3% | 4.3% | 4.29x | 4.13x | 12.7x | 11.6x | 17.0x | 14.5x | 69.6% | 33.7% | 20.1% |
| MRK | Merck & Co., Inc. | 79.16 | 198,773 | 224,454 | 64,168 | 29,134 | -9.1% | -38.1% | 3.50x | 3.43x | 7.7x | 7.3x | 11.5x | 8.8x | 77.1% | 45.4% | 40.8% |
| PFE | Pfizer Inc. | 24.24 | 137,813 | 183,190 | 63,627 | 23,322 | -1.2% | -14.1% | 2.88x | 2.94x | 7.9x | 7.6x | 17.5x | 8.6x | 74.2% | 36.7% | 9.1% |
| Median | | | \$206,885 | \$233,731 | \$51,187 | \$19,338 | -4.4% | -3.0% | 4.93x | 4.73x | 12.9x | 11.3x | 20.5x | 14.1x | 74.7% | 41.5% | 25.5% |

Source: CapIQ with Mercer Analysis

BioTech

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Re | venue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|---------------------------------|-------------|-----------|-----------|----------|----------|------------|---------|--------|--------|-------|--------|--------|-------|--------|---------|--------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| ABT | Abbott Laboratories | \$136.01 | \$236,635 | \$243,334 | \$41,950 | \$10,714 | 3.3% | 31.8% | 5.80x | 5.35x | 22.7x | 20.2x | 17.7x | 25.8x | 55.6% | 25.5% | 30.9% |
| ALNY | Alnylam Pharmaceuticals, Inc. | 326.09 | 42,518 | 42,608 | 2,248 | -120 | 27.5% | 34.0% | 18.95x | 12.99x | NM | 182.3x | NM | nm | 85.6% | -5.3% | 362.3% |
| BIIB | Biogen Inc. | 125.59 | 18,402 | 22,425 | 9,676 | 2,996 | -4.9% | -45.8% | 2.32x | 2.43x | 7.5x | 6.0x | 12.4x | 8.0x | 76.1% | 31.0% | 10.4% |
| BSX | Boston Scientific Corporation | 107.41 | 158,907 | 170,123 | 16,747 | 4,271 | 6.1% | 40.6% | 10.16x | 8.48x | 39.8x | 28.9x | 78.4x | 36.4x | 68.4% | 25.5% | 8.9% |
| INCY | Incyte Corporation | 68.10 | 13,182 | 10,817 | 4,241 | 178 | 11.8% | 11.9% | 2.55x | 2.25x | 60.9x | 7.4x | NM | 11.4x | 35.0% | 4.2% | 0.8% |
| KRYS | Krystal Biotech, Inc. | 137.46 | 3,972 | 3,217 | 291 | 106 | -21.3% | -24.6% | 11.07x | 7.52x | 30.4x | 16.5x | 33.1x | 23.1x | 93.1% | 36.4% | 10.3% |
| MRNA | Moderna, Inc. | 27.59 | 10,670 | 3,022 | 3,236 | -3,756 | 1.6% | -76.2% | 0.93x | 2.27x | NM | nm | NM | nm | -85.6% | -116.1% | -28.8% |
| REGN | Regeneron Pharmaceuticals, Inc. | 525.00 | 55,474 | 40,554 | 14,202 | 4,628 | -14.9% | -50.3% | 2.86x | 3.64x | 8.8x | 11.6x | 13.3x | 14.5x | 50.0% | 32.6% | 16.0% |
| SRPT | Sarepta Therapeutics, Inc. | 17.10 | 1,681 | 2,515 | 1,902 | 256 | -72.4% | -89.1% | 1.32x | 1.11x | 9.8x | nm | NM | 15.5x | 40.9% | 13.4% | 19.7% |
| VRTX | Vertex Pharmaceuticals Inc. | 445.20 | 114,326 | 104,618 | 11,020 | 4,775 | -8.2% | -5.5% | 9.49x | 8.83x | 21.9x | 18.0x | NM | 23.6x | 54.7% | 43.3% | -3.2% |
| Median | | | \$30,460 | \$31,489 | \$6,959 | \$1,626 | -1.6% | -15.1% | 4.33x | 4.49x | 22.3x | 17.2x | 17.7x | 19.3x | 55.1% | 25.5% | 10.4% |

Source: CapIQ with Mercer Analysis

Healthcare Providers

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Rev | enue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|---------------------------------|-------------|----------|----------|----------|---------|------------|---------|--------|-------|-------|-------|--------|-------|-------|--------|--------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| CYH | Community Health Systems, Inc. | \$3.40 | \$455 | \$12,597 | \$12,634 | \$1,249 | 31.3% | 2.4% | 1.00x | 0.96x | 10.1x | 7.9x | nm | nm | 41.7% | 9.9% | 33.8% |
| ELV | Elevance Health, Inc. | 388.96 | 87,880 | 110,500 | 176,810 | 9,856 | -10.1% | -27.2% | 0.62x | 0.42x | 11.2x | 6.4x | 15.2x | 11.0x | 27.9% | 5.6% | 14.8% |
| EHC | Encompass Health Corporation | 122.63 | 12,361 | 15,746 | 5,373 | 1,175 | 21.1% | 43.7% | 2.93x | 2.58x | 13.4x | 12.6x | 25.3x | 23.9x | 41.6% | 21.9% | 23.3% |
| HCA | HCA Healthcare, Inc. | 383.10 | 92,164 | 140,514 | 70,603 | 13,859 | 10.8% | 21.6% | 1.99x | 1.83x | 10.1x | 9.3x | 17.1x | 14.7x | 40.6% | 19.6% | 824.4% |
| LH | Labcorp Holdings Inc. | 262.51 | 21,972 | 28,202 | 13,009 | 1,701 | 12.8% | 29.2% | 2.17x | 1.94x | 16.6x | 11.3x | 30.3x | 16.0x | 27.9% | 13.1% | 9.4% |
| SEM | Select Medical Holdings Corp. | 15.18 | 1,951 | 5,012 | 5,187 | 411 | -8.0% | -57.3% | 0.97x | 0.74x | 12.2x | 7.7x | 11.1x | 14.0x | 17.7% | 7.9% | 7.3% |
| THC | Tenet Healthcare Corporation | 176.00 | 16,348 | 30,991 | 20,665 | 4,036 | 31.9% | 32.0% | 1.50x | 1.49x | 7.7x | 7.6x | 11.7x | 13.9x | 39.7% | 19.5% | 57.8% |
| CI | The Cigna Group | 330.58 | 88,312 | 109,887 | 247,121 | 11,446 | -0.1% | 1.3% | 0.44x | 0.43x | 9.6x | 8.6x | 18.4x | 10.6x | 10.5% | 4.6% | 8.6% |
| ENSG | The Ensign Group, Inc. | 154.26 | 8,804 | 10,472 | 4,260 | 443 | 18.3% | 24.3% | 2.46x | 1.70x | 23.6x | 14.7x | 29.1x | 23.8x | 16.3% | 10.4% | 17.9% |
| UHS | Universal Health Services, Inc. | 181.15 | 11,673 | 16,741 | 15,828 | 2,270 | -3.5% | -0.6% | 1.06x | 0.94x | 7.4x | 6.6x | 10.2x | 9.1x | 42.5% | 14.3% | 17.9% |
| Median | | | \$14,354 | \$22,471 | \$14,418 | \$1,986 | 11.8% | 12.0% | 1.28x | 1.23x | 10.7x | 8.2x | 17.1x | 14.0x | 33.8% | 11.7% | 17.9% |

Source: CapIQ with Mercer Analysis



WWW.MERCERCAPITAL.COM

HEALTHCARE SNAPSHOT: Stocks

Healthcare Services

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perl | ormance | EV/Rev | /enue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|----------------------------------|-------------|----------|----------|----------|---------|------------|---------|--------|-------|-------|-------|--------|-------|-------|--------|--------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| ALHC | Alignment Healthcare, Inc. | \$14.00 | \$2,770 | \$2,654 | \$2,704 | -\$71 | -22.6% | 75.7% | 0.98x | 0.65x | NM | 42.4x | nm | nm | 11.0% | -2.6% | -98.9% |
| AMN | AMN Healthcare Services, Inc. | 20.67 | 791 | 1,773 | 2,984 | 294 | -13.2% | -58.1% | 0.59x | 0.65x | 6.0x | 8.0x | NA | 20.0x | 30.8% | 9.8% | -19.1% |
| CNC | Centene Corporation | 54.28 | 27,010 | 30,618 | 147,169 | 6,188 | -10.2% | -16.9% | 0.21x | 0.16x | 4.9x | 6.2x | 8.1x | 7.2x | 14.6% | 4.2% | 12.6% |
| CLOV | Clover Health Investments, Corp. | 2.79 | 1,420 | 1,264 | 1,371 | -45 | -22.3% | 132.5% | 0.92x | 0.64x | NM | 20.4x | NM | nm | 26.6% | -3.3% | -14.8% |
| CVS | CVS Health Corporation | 68.98 | 87,261 | 156,001 | 370,656 | 12,616 | 1.5% | 18.6% | 0.42x | 0.36x | 12.4x | 8.6x | 16.5x | 11.2x | 13.3% | 3.4% | 6.0% |
| HQY | HealthEquity, Inc. | 104.76 | 9,059 | 9,878 | 1,200 | 365 | 20.3% | 20.9% | 8.23x | 7.39x | 27.0x | 17.4x | 76.5x | 27.1x | 64.8% | 30.4% | 4.7% |
| HUM | Humana Inc. | 244.48 | 29,507 | 39,059 | 117,761 | 3,351 | -7.7% | -34.5% | 0.33x | 0.17x | 11.7x | 5.5x | 17.3x | 15.8x | 14.5% | 2.8% | 7.4% |
| МОН | Molina Healthcare, Inc. | 297.90 | 16,146 | 15,056 | 39,164 | 1,825 | -9.1% | 2.0% | 0.38x | 0.24x | 8.2x | 5.1x | 14.4x | 11.8x | 12.1% | 4.7% | 27.1% |
| PINC | Premier, Inc. | 21.93 | 1,806 | 2,029 | 1,346 | 412 | 12.6% | 18.0% | 1.51x | 2.06x | 4.9x | 8.3x | 34.6x | 16.0x | 66.0% | 30.6% | 5.0% |
| UNH | UnitedHealth Group Incorporated | 311.97 | 283,001 | 343,686 | 400,278 | 34,986 | -40.4% | -36.9% | 0.86x | 0.75x | 9.8x | 10.3x | 13.1x | 13.9x | 22.3% | 8.7% | 15.1% |
| Median | | | \$12,603 | \$12,467 | \$21,074 | \$1,119 | -9.7% | 10.0% | 0.73x | 0.64x | 9.0x | 8.4x | 16.5x | 14.9x | 18.5% | 4.4% | 5.5% |

Source: CapIQ with Mercer Analysis



Medical Devices and Technology

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Re | venue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|----------------------------------|-------------|----------|----------|---------|---------|------------|---------|--------|--------|-------|-------|--------|-------|-------|--------|--------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| DXCM | DexCom, Inc. | \$87.29 | \$34,227 | \$34,109 | \$4,033 | \$818 | 29.7% | -22.2% | 8.46x | 7.13x | 41.7x | 22.9x | 65.5x | 39.8x | 60.5% | 20.3% | 27.6% |
| EW | Edwards Lifesciences Corporation | 78.21 | 45,878 | 42,736 | 5,440 | 1,636 | 8.8% | -13.3% | 7.86x | 7.08x | 26.1x | 23.9x | 11.1x | 31.6x | 79.5% | 30.1% | 16.6% |
| IDXX | IDEXX Laboratories, Inc. | 536.34 | 43,133 | 44,029 | 3,898 | 1,320 | 28.1% | 12.6% | 11.30x | 10.43x | 33.4x | 30.2x | 49.6x | 43.0x | 61.0% | 33.9% | 57.7% |
| PODD | Insulet Corporation | 314.18 | 22,110 | 22,576 | 2,072 | 390 | 19.4% | 60.2% | 10.90x | 8.56x | 57.9x | 36.4x | 56.6x | 70.5x | 69.8% | 18.8% | 43.0% |
| ITGR | Integer Holdings Corporation | 122.97 | 4,291 | 5,614 | 1,717 | 333 | 3.7% | 6.8% | 3.27x | 2.90x | 16.9x | 13.1x | 56.4x | 18.6x | 26.9% | 19.4% | 7.7% |
| MDT | Medtronic plc | 87.17 | 111,688 | 132,564 | 33,537 | 9,113 | -1.5% | 13.0% | 3.95x | 3.73x | 14.5x | 13.0x | 24.2x | 15.7x | 65.4% | 27.2% | 9.5% |
| STE | STERIS plc | 240.22 | 23,631 | 25,674 | 5,460 | 1,464 | 6.4% | 9.9% | 4.70x | 4.38x | 17.5x | 16.0x | 38.7x | 23.9x | 44.3% | 26.8% | 9.5% |
| SYK | Stryker Corporation | 395.63 | 151,196 | 166,143 | 22,595 | 6,006 | 6.0% | 17.6% | 7.35x | 6.57x | 27.7x | 23.6x | 53.5x | 29.1x | 64.4% | 26.6% | 15.3% |
| TNDM | Tandem Diabetes Care, Inc. | 18.64 | 1,242 | 1,371 | 940 | -83 | -0.5% | -52.8% | 1.46x | 1.20x | NM | 30.8x | NM | nm | 52.1% | -8.8% | -33.3% |
| ZBH | Zimmer Biomet Holdings, Inc. | 91.21 | 18,046 | 23,995 | 7,679 | 2,590 | -18.8% | -13.9% | 3.12x | 2.88x | 9.3x | 8.8x | 20.2x | 11.4x | 71.6% | 33.7% | 7.3% |
| Median | | | \$28,929 | \$29,891 | \$4,736 | \$1,392 | 6.2% | 8.4% | 6.03x | 5.48x | 26.1x | 23.2x | 49.6x | 29.1x | 62.7% | 26.7% | 12.4% |

Source: CapIQ with Mercer Analysis



Life Sciences Tools

| | | 6/30/25 | Mkt Cap | | Revenue | EBITDA | Share Perf | ormance | EV/Rev | venue | EV/EB | ITDA | Price/ | EPS | Gross | EBITDA | ROE |
|--------|--|-------------|----------|----------|---------|---------|------------|---------|--------|-------|-------|-------|--------|-------|-------|--------|---------|
| Ticker | Name | Stock Price | (\$M) | EV (\$M) | (\$M) | (\$M) | %Q/Q | %Y/Y | LTM | NTM | LTM | NTM | LTM | NTM | LTM | LTM | LTM |
| Α | Agilent Technologies, Inc. | \$118.01 | \$33,522 | \$35,721 | \$6,510 | \$1,801 | 3.5% | -7.4% | 5.49x | 5.11x | 19.8x | 16.7x | 29.1x | 20.3x | 54.3% | 27.7% | 22.0% |
| AVTR | Avantor, Inc. | 13.46 | 9,172 | 12,963 | 6,784 | 1,131 | -14.8% | -35.2% | 1.91x | 1.92x | 11.5x | 10.8x | 12.9x | 12.8x | 33.6% | 16.7% | 12.7% |
| BRKR | Bruker Corporation | 41.20 | 6,243 | 8,216 | 3,366 | 594 | 2.0% | -33.9% | 2.44x | 2.32x | 13.8x | 12.7x | 78.5x | 16.3x | 50.0% | 17.6% | 7.1% |
| CRL | Charles River Laboratories International, Inc. | 151.73 | 7,452 | 10,260 | 4,050 | 898 | 3.9% | -25.3% | 2.53x | 2.50x | 11.4x | 10.3x | NM | 15.5x | 34.8% | 22.2% | 0.7% |
| DHR | Danaher Corporation | 197.54 | 141,373 | 156,965 | 23,875 | 7,506 | -1.4% | -19.2% | 6.57x | 6.27x | 20.9x | 19.9x | 38.3x | 25.2x | 59.6% | 31.4% | 7.6% |
| ILMN | Illumina, Inc. | 95.41 | 15,103 | 16,473 | 4,372 | 754 | 21.7% | -9.6% | 3.77x | 3.74x | 21.8x | 14.2x | NM | 22.1x | 68.4% | 17.2% | -30.1% |
| IQV | IQVIA Holdings Inc. | 157.59 | 27,263 | 39,933 | 15,405 | 2,921 | -8.0% | -24.4% | 2.59x | 2.49x | 13.7x | 10.5x | 21.5x | 13.0x | 34.9% | 19.0% | 22.6% |
| MTD | Mettler-Toledo International Inc. | 1,174.72 | 24,414 | 26,424 | 3,872 | 1,212 | 1.6% | -14.1% | 6.82x | 6.68x | 21.8x | 21.2x | 29.3x | 27.5x | 60.1% | 31.3% | -623.6% |
| RVTY | Revvity, Inc. | 96.72 | 11,400 | 13,588 | 2,755 | 838 | -7.3% | -6.1% | 4.93x | 4.65x | 16.2x | 15.1x | 41.2x | 19.0x | 55.8% | 30.4% | 3.6% |
| WAT | Waters Corporation | 349.04 | 20,771 | 21,930 | 2,958 | 1,029 | -2.0% | 23.5% | 7.41x | 6.93x | 21.3x | 19.0x | 31.7x | 26.3x | 59.4% | 34.8% | 42.8% |
| Median | | | \$17,937 | \$19,202 | \$4,211 | \$1,080 | 0.1% | -16.6% | 4.35x | 4.19x | 18.0x | 14.6x | 30.5x | 19.7x | 55.1% | 24.9% | 7.3% |

Source: CapIQ with Mercer Analysis

HEALTHCARE SNAPSHOT: Initial Public Offerings

Completed Initial Public Offerings During 2Q 2025

| Issuer | Ticker | IPO Date | IPO Price (\$) | Gross Proceeds(\$M) | 6/30/25 Stock Price | Return Since IPO | 6/30/25 Market Cap (\$M) | Industry |
|----------------------------------|---------------|----------|----------------|------------------------|------------------------|---------------------|--------------------------------|-----------------|
| Caris Life Sciences, Inc. | NasdaqGS:CAI | 6/17/25 | \$27.00 | \$494.12 | \$26.72 | -1.0% | \$7,860.00 | Biotechnology |
| Omada Health, Inc. | NasdaqGS:OMDA | 6/5/25 | 23.00 | 150.10 | 18.30 | -20.4% | 1,039.00 | Telehealth |
| Hinge Health, Inc. | NYSE:HNGE | 5/21/25 | 39.50 | 437.31 | 51.75 | 31.0% | 3,581.00 | Health Software |
| Apimeds Pharmaceuticals US, Inc. | NYSEAM:APUS | 5/8/25 | 4.00 | 13.50 | 1.76 | -56.0% | 23.38 | Pharmaceuticals |

Source: CapIQ with Mercer Analysis

HEALTHCARE SNAPSHOT: Private Equity M&A

PE Healthcare Deals Q2 2025

| Date | Target | Buyer | Sector |
|---------|---|---|----------------------------------|
| 6/30/25 | Alphalyse A/S | Fidelio Capital AB | Biotechnology |
| 6/30/25 | ImmersiveTouch, Inc. | HealthpointCapital, LLC | Health Care Technology |
| 6/26/25 | G21 S.R.L. | G Square Healthcare Private Equity LLP | Pharmaceuticals |
| 6/26/25 | Synthego Corporation | Perceptive Advisors LLC | Life Sciences Tools and Services |
| 6/24/25 | HospitalNet Inc. | Nihon PMI Partners Co., Ltd.; Chiiki Iryo Kasseika Healthcare Fund | Health Care Equipment |
| 6/13/25 | Strong Room Technology Pty Ltd | InterValley Ventures | Health Care Technology |
| 6/11/25 | Med-gastr Sp. z o.o. Sp.k. | Tar Heel Capital Sp. Z oo | Health Care Facilities |
| 6/9/25 | ITH Group Limited | H.I.G. Capital, LLC | Health Care Services |
| 6/9/25 | Optimal Health Associates | Casla Partners, LLC | Health Care Services |
| 6/4/25 | EBI, LLC | Avista Healthcare Partners | Health Care Equipment |
| 6/3/25 | MAS Technicae Group (International) Ltd | Accel-KKR LLC | Health Care Technology |
| 5/28/25 | Intuitive Care Hospital Intelligence Inc. | Arcadea Group Inc. | Health Care Technology |
| 5/27/25 | DAS Health Ventures, Inc. | Coalesce Capital Management, LLC | Health Care Technology |
| 5/13/25 | Oehm und Rehbein GmbH | Nord Holding | Health Care Equipment |
| 5/12/25 | Axitare Ltd | Vaaka Partners Oy | Health Care Equipment |
| 5/12/25 | Paradigm Living Concepts, LLC | Cressey & Company LP; Havencrest Capital Management, LLC | Health Care Facilities |
| 5/9/25 | Ipractice B.v. | Smile Invest NV | Health Care Services |
| 5/5/25 | Behavior Frontiers, LLC | NexPhase Capital, LP | Health Care Services |
| 5/1/25 | Hive Networks, Inc. | Vora Ventures LLC | Health Care Technology |
| 4/30/25 | Dental Iberica 2008 SI | Miura Partners SGEIC, S.A.; Dent&Co | Health Care Services |
| 4/15/25 | American Outcomes Management L.P. | Revelstoke Capital Partners LLC; Revelstoke Capital Partners Fund III | Health Care Services |
| 4/7/25 | GetixHealth, LLC | H.I.G. Capital, LLC | Health Care Services |
| 4/3/25 | Summit Spine & Joint Centers | Wellspring Capital Management LLC; MSouth Equity Partners, LLC | Health Care Services |
| 4/1/25 | Warwick Sasco Limited | Karnell Group AB (publ) (OM:KARNEL B) | Health Care Supplies |
| | | | |

HEALTHCARE SNAPSHOT: Healthcare Facilities M&A

Healthcare Facilities M&A Deals Q2 2025

| Date | Issuer | Buyer | Transaction Value |
|---------|--|--|-------------------|
| 6/20/25 | ARPAVIE | Groupe Sos Seniors | NA |
| 6/9/25 | UMMC Madison | University Of Mississippi Medical Center | NA |
| 6/2/25 | Dermatology Centers of Northeastern Pennsylvania | Dermdox Dermatology Centers Pc | NA |
| 5/29/25 | The Bellevue Hospital Corporation | Firelands Regional Medical Center | NA |
| 5/1/25 | Ai Life Service Co., Ltd. | SaintNACare Holding Corporation (TSE:2374) | NA |
| 4/30/25 | Potomac Urology Center LLC | The GI Alliance Management, LLC | NA |
| 4/17/25 | Atlanta Osteoarthritis Center LLC | IHS, LLC. | NA |
| 4/17/25 | North Florida Retirement Village, Inc. | Fortress Investment Group LLC | NA |
| 4/15/25 | Cedar Park Health System, L.P. | Ascension Texas | 436.00 |
| 4/15/25 | Geriavi, SAU | Inia Neural, SL | 113.16 |
| 4/15/25 | Pinnacle Surgery Center, LLC | AMSURG Corp. | NA |
| 4/8/25 | Logansport Memorial Hospital | Parkview Health System, Inc. | NA |

Source: CapIQ with Mercer Analysis

MERCER CAPITAL'S HEALTHCARE FACILITIES INDUSTRY SERVICES



>> Click here to learn more about our services

Mercer Capital provides valuation and advisory services to a wide range of healthcare facilities.

Healthcare Facilities Industry Segments:

- Acute Care Hospitals
- · Assisted Living Facilities
- Dental Service Organizations
- Emergency Services
- Home Care and Hospice
- Long-Term Care
- Surgical Centers and Rehabilitation Facilities
- Other Healthcare Facilities

Contact a Mercer Capital professional to discuss your needs in confidence.

Services Provided:

- Valuation of Healthcare Companies for Tax Compliance
- Valuation for Purchase Accounting and Impairment Testing
- Fairness and Solvency Opinions
- Transaction Advisory for Acquisitions and Divestitures
- Litigation Support for Economic Damages, Valuation, and Shareholder Disputes

HEALTHCARE FACILITIES INDUSTRY VALUATION TEAM



Sujan Rajbhandary, CFA, ABV 901.322.9749 sujanr@mercercapital.com



Nicholas J. Heinz, ASA 901.322.9788 heinzn@mercercapital.com



Travis W. Harms, CFA, CPA/ABV 901.322.9760 harmst@mercercapital.com



J. David Smith, ASA, CFA 713.239.1005 smithd@mercercapital.com



J. Davis Rolfe, Jr., CPA 901.322.9712 rolfed@mercercapital.com